Optimization on the dose and time of nicaraven administration for mitigating the side effects of radiotherapy in a preclinical tumor-bearing mouse model.

Xu, Yong; Abdelghany, Lina; Sekiya, Reiko; Zhai, Da; Jingu, Keiichi; Li, Tao-Sheng

Xu, Yong; Abdelghany, Lina; Sekiya, Reiko; Zhai, Da; Jingu, Keiichi; Li, Tao-Sheng.

Afiliação

Xu Y; Department of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Abdelghany L; Department of Stem Cell Biology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Sekiya R; Department of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Zhai D; Department of Stem Cell Biology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Jingu K; Department of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Li TS; Department of Stem Cell Biology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.

Ther Adv Respir Dis ; 16: 17534666221137277, 2022.

Article em En | MEDLINE | ID: mdl-36404753

Assuntos

Neoplasias; Niacinamida; Camundongos; Humanos; Animais; Camundongos Endogâmicos C57BL; Niacinamida/farmacologia; Fator de Crescimento Transformador beta

Palavras-chave

DNA damage; fibrosis; inflammatory response; lung injury; radiation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Niacinamida / Neoplasias Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Ther Adv Respir Dis Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google